{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T19:59:43Z","timestamp":1770839983021,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T00:00:00Z","timestamp":1663027200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001511","name":"Auckland Medical Research Foundation","doi-asserted-by":"publisher","award":["1120011"],"award-info":[{"award-number":["1120011"]}],"id":[{"id":"10.13039\/501100001511","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Cancer Research Trust NZ","award":["2009RPG"],"award-info":[{"award-number":["2009RPG"]}]},{"name":"Gut Cancer Foundation NZ"},{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proton Pump Inhibitors (PPI) rank within the top ten most prescribed medications in Europe and USA. A high frequency of PPI use has been reported amongst patients undergoing chemotherapy, to mitigate treatment-induced gastritis or gastro-oesophageal reflux. Several recent, mostly retrospective, observational studies have reported inferior survival outcomes among patients on capecitabine who concomitantly use PPI. Whilst this association is yet to be definitively established, given the prominence of capecitabine as an anti-cancer treatment with multiple indications, these reports have raised concern within the oncological community and drug regulatory bodies worldwide. Currently, the leading mechanism of interaction postulated in these reports has focussed on the pH altering effects of PPI and how this could diminish capecitabine absorption, leading to a decrease in its bioavailability. In this discourse, we endeavour to summarise plausible pharmacokinetic interactions between PPI and capecitabine. We provide a basis for our argument against the currently proposed mechanism of interaction. We also highlight the long-term effects of PPI on health outcomes, and how PPI use itself could lead to poorer outcomes, independent of capecitabine.<\/jats:p>","DOI":"10.1007\/s00280-022-04473-9","type":"journal-article","created":{"date-parts":[[2022,9,13]],"date-time":"2022-09-13T13:06:58Z","timestamp":1663074418000},"page":"381-388","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Re-thinking the possible interaction between proton pump inhibitors and capecitabine"],"prefix":"10.1007","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5984-1280","authenticated-orcid":false,"given":"Soo Hee","family":"Jeong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lara","family":"Molloy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1841-7261","authenticated-orcid":false,"given":"Edmond","family":"Ang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-5368","authenticated-orcid":false,"given":"Nuala","family":"Helsby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,9,13]]},"reference":[{"issue":"2","key":"4473_CR1","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/clpt.2012.73","volume":"92","author":"N Budha","year":"2012","unstructured":"Budha N, Frymoyer A, Smelick G, Jin J, Yago M, Dresser M, Holden S, Benet L, Ware J (2012) Drug absorption interactions between oral targeted anticancer agents and PPIs: is pH-dependent solubility the Achilles heel of targeted therapy? Clin Pharm Therap 92(2):203\u2013213. https:\/\/doi.org\/10.1038\/clpt.2012.73","journal-title":"Clin Pharm Therap"},{"issue":"8","key":"4473_CR2","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1007\/s12094-019-02254-0","volume":"22","author":"D Vi\u00f1al","year":"2020","unstructured":"Vi\u00f1al D, Rodriguez-Salas N, Perez-Wert P, Higuera O, Ghanem I, Feliu J (2020) Efficacy of capecitabine when used concomitantly with proton pump inhibitors in cancer patients: a systematic review. Clin Transl Oncol 22(8):1288\u20131294. https:\/\/doi.org\/10.1007\/s12094-019-02254-0","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"4473_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.clcc.2015.12.008","volume":"15","author":"J Sun","year":"2016","unstructured":"Sun J, Ilich AI, Kim CA, Chu MP, Wong GG, Ghosh S, Danilak M, Mulder KE, Spratlin JL, Chambers CR (2016) Concomitant administration of proton pump inhibitors and capecitabine is associated with increased recurrence risk in early stage colorectal cancer patients. Clin Colorectal Cancer 15(3):257\u2013263. https:\/\/doi.org\/10.1016\/j.clcc.2015.12.008","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"4473_CR4","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1001\/jamaoncol.2016.3358","volume":"3","author":"MP Chu","year":"2017","unstructured":"Chu MP, Hecht JR, Slamon D, Wainberg ZA, Bang Y-J, Hoff PM, Sobrero A, Qin S, Afenjar K, Houe V (2017) Association of proton pump inhibitors and capecitabine efficacy in advanced gastroesophageal cancer: secondary analysis of the TRIO-013\/LOGiC randomized clinical trial. JAMA Oncol 3(6):767\u2013773. https:\/\/doi.org\/10.1001\/jamaoncol.2016.3358","journal-title":"JAMA Oncol"},{"issue":"8","key":"4473_CR5","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1177\/1078155218818237","volume":"25","author":"HE Rhinehart","year":"2019","unstructured":"Rhinehart HE, Phillips MA, Wade N, Baran A (2019) Evaluation of the clinical impact of concomitant acid suppression therapy in colorectal cancer patients treated with capecitabine monotherapy. J Oncol Pharm 25(8):1839\u20131845. https:\/\/doi.org\/10.1177\/1078155218818237","journal-title":"J Oncol Pharm"},{"issue":"1","key":"4473_CR6","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.clcc.2018.11.001","volume":"18","author":"GG Wong","year":"2019","unstructured":"Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB (2019) Effects of proton pump inhibitors on FOLFOX and CapeOx regimens in colorectal cancer. Clin Colorectal Cancer 18(1):72\u201379. https:\/\/doi.org\/10.1016\/j.clcc.2018.11.001","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"4473_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-022-10008-2","volume":"12","author":"Y Kitazume","year":"2022","unstructured":"Kitazume Y, Kawazoe H, Uozumi R, Yoshizawa T, Iihara H, Fujii H, Takahashi M, Arai T, Murachi Y, Sato Y (2022) Proton pump inhibitors affect capecitabine efficacy in patients with stage II\u2013III colorectal cancer: a multicenter retrospective study. Sci Rep 12(1):1\u201310. https:\/\/doi.org\/10.1038\/s41598-022-10008-2","journal-title":"Sci Rep"},{"issue":"6","key":"4473_CR8","doi-asserted-by":"publisher","first-page":"e954","DOI":"10.1002\/onco.13735","volume":"26","author":"SY Kim","year":"2021","unstructured":"Kim SY, Lee JS, Kang J, Morita S, Park YS, Sakamoto J, Muro K, Xu RH, Kim TW (2021) Proton pump inhibitor use and the efficacy of chemotherapy in metastatic colorectal cancer: a post hoc analysis of a randomized phase III trial (AXEPT). Oncologist 26(6):e954\u2013e962. https:\/\/doi.org\/10.1002\/onco.13735","journal-title":"Oncologist"},{"issue":"35","key":"4473_CR9","doi-asserted-by":"publisher","first-page":"58801","DOI":"10.18632\/oncotarget.18522","volume":"8","author":"X Wang","year":"2017","unstructured":"Wang X, Liu C, Wang J, Fan Y, Wang Z, Wang Y (2017) Proton pump inhibitors increase the chemosensitivity of patients with advanced colorectal cancer. Oncotarget 8(35):58801. https:\/\/doi.org\/10.18632\/oncotarget.18522","journal-title":"Oncotarget"},{"key":"4473_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2020.7670","volume":"1","author":"G Kichenadasse","year":"2021","unstructured":"Kichenadasse G, Miners JO, Mangoni AA, Karapetis CS, Hopkins AM, Sorich MJ (2021) Proton pump inhibitors and survival in patients with colorectal cancer receiving fluoropyrimidine-based chemotherapy. J Natl Compr Canc Netw 1:1\u20138. https:\/\/doi.org\/10.6004\/jnccn.2020.7670","journal-title":"J Natl Compr Canc Netw"},{"issue":"9","key":"4473_CR11","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1097\/COC.0000000000000850","volume":"44","author":"A Menon","year":"2021","unstructured":"Menon A, Abraham AG, Mahfouz M, Thachuthara JJ, Usmani N, Warkentin H, Ghosh S, Nijjar T, Severin D, Tankel K (2021) Concomitant use of proton pump inhibitors with capecitabine based neoadjuvant chemoradiotherapy for locally advanced rectal cancer: is it safe? Am J Clin Oncol 44(9):487\u2013494. https:\/\/doi.org\/10.1097\/COC.0000000000000850","journal-title":"Am J Clin Oncol"},{"issue":"14","key":"4473_CR12","doi-asserted-by":"publisher","first-page":"2575","DOI":"10.3748\/wjg.v23.i14.2575","volume":"23","author":"J-L Zhang","year":"2017","unstructured":"Zhang J-L, Liu M, Yang Q, Lin S-Y, Shan H-B, Wang H-Y, Xu G-L (2017) Effects of omeprazole in improving concurrent chemoradiotherapy efficacy in rectal cancer. World J Gastroenterol 23(14):2575. https:\/\/doi.org\/10.3748\/wjg.v23.i14.2575","journal-title":"World J Gastroenterol"},{"key":"4473_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s12029-022-00825-z","author":"M Bridoux","year":"2022","unstructured":"Bridoux M, Le Deley M-C, Bertrand N, Simon N, Sylla D, Mirabel X, Turpin A (2022) Effects of proton pump inhibitors intake during chemoradiotherapy for rectal cancer: a retrospective cohort study. J Gastrointest Cancer. https:\/\/doi.org\/10.1007\/s12029-022-00825-z","journal-title":"J Gastrointest Cancer"},{"key":"4473_CR14","doi-asserted-by":"publisher","first-page":"iv43","DOI":"10.1093\/annonc\/mdz155.159","volume":"30","author":"M Roberto","year":"2019","unstructured":"Roberto M, Arrivi G, Milano A, D\u2019Antonio C, Romiti A, Falcone R, Mazzuca F, Fais S, Marchetti P (2019) Updated results of a phase II randomized trial with high dose proton pump inhibitors and metronomic capecitabine as salvage treatment for patients with advanced gastrointestinal tumours. Ann Oncol 30:iv43\u2013iv44. https:\/\/doi.org\/10.1093\/annonc\/mdz155.159","journal-title":"Ann Oncol"},{"key":"4473_CR15","unstructured":"Yang, J.Y., H.K. Sanoff, R.S. Sandler, T. Sturmer, M.J. Funk, and J.L. Lund (2017) Does proton-pump inhibitor use diminish capecitabine efficacy in advanced cancer patients? In: Pharmacoepidemiol Drug Saf. Wiley, Hoboken, pp 07030\u201315774"},{"issue":"9","key":"4473_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3760\/cma.j.issn.0253-3766.2019.09.012","volume":"41","author":"C Lu","year":"2019","unstructured":"Lu C, Zheng B, Bai B, Hu J, Fan S, Shang D, Yang D, Zhao C, Cang S (2019) Effect of omeprazole on plasma concentration and adverse reactions of capecitabine in patients with colon cancer. Zhonghua zhong liu za zhi [Chinese J Oncol] 41(9):708\u2013711. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-3766.2019.09.012","journal-title":"Zhonghua zhong liu za zhi [Chinese J Oncol]"},{"issue":"1","key":"4473_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-021-88460-9","volume":"11","author":"S Hiromoto","year":"2021","unstructured":"Hiromoto S, Kawashiri T, Yamanaka N, Kobayashi D, Mine K, Inoue M, Uchida M, Shimazoe T (2021) Use of omeprazole, the proton pump inhibitor, as a potential therapy for the capecitabine-induced hand-foot syndrome. Sci Rep 11(1):1\u20136. https:\/\/doi.org\/10.1038\/s41598-021-88460-9","journal-title":"Sci Rep"},{"issue":"11","key":"4473_CR18","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1007\/s10620-009-0951-9","volume":"54","author":"RR Kedika","year":"2009","unstructured":"Kedika RR, Souza RF, Spechler SJ (2009) Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci 54(11):2312\u20132317. https:\/\/doi.org\/10.1007\/s10620-009-0951-9","journal-title":"Dig Dis Sci"},{"issue":"4","key":"4473_CR19","first-page":"941","volume":"4","author":"B Reigner","year":"1998","unstructured":"Reigner B, Verweij J, Dirix L, Cassidy J, Twelves C, Allman D, Weidekamm E, Roos B, Banken L, Utoh M (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941\u2013948","journal-title":"Clin Cancer Res"},{"issue":"7","key":"4473_CR20","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1177\/1078155219846952","volume":"25","author":"V Cheng","year":"2019","unstructured":"Cheng V, M.d. Lemos, N. Hunter, N. Badry, and J.d. Lemos, (2019) Concomitant use of capecitabine and proton pump inhibitors\u2013Is it safe? J Oncol Pharm 25(7):1705\u20131711. https:\/\/doi.org\/10.1177\/1078155219846952","journal-title":"J Oncol Pharm"},{"key":"4473_CR21","unstructured":"European Medicines Agency (2012) Capecitabine Accord Assessment Report (Procedure No. EMEA\/H\/C\/002386)."},{"issue":"11","key":"4473_CR22","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1093\/annonc\/mdn662","volume":"19","author":"L Chaigneau","year":"2008","unstructured":"Chaigneau L, Royer B, Montange D, Nguyen T, Maurina T, Villanueva C, Demarchi M, Borg C, Fagnoni-Legat C, Kantelip J-P (2008) Influence of capecitabine absorption on its metabolites pharmacokinetics: a bioequivalence study. Ann Oncol 19(11):1980\u20131981. https:\/\/doi.org\/10.1093\/annonc\/mdn662","journal-title":"Ann Oncol"},{"issue":"3","key":"4473_CR23","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1111\/j.1365-2125.1974.tb00234.x","volume":"1","author":"L Prescott","year":"1974","unstructured":"Prescott L (1974) Gastric emptying and drug absorption. Br J Clin Pharmacol 1(3):189. https:\/\/doi.org\/10.1111\/j.1365-2125.1974.tb00234.x","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"4473_CR24","first-page":"183","volume":"46","author":"J Fallingborg","year":"1999","unstructured":"Fallingborg J (1999) Intraluminal pH of the human gastrointestinal tract. Dan Med Bull 46(3):183\u2013196","journal-title":"Dan Med Bull"},{"key":"4473_CR25","unstructured":"National Center for Biotechnology Information (2021) PubChem Compound Summary for CID 60953, Capecitabine"},{"issue":"12","key":"4473_CR26","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/psp4.12474","volume":"8","author":"BA Jacobs","year":"2019","unstructured":"Jacobs BA, Deenen MJ, Joerger M, Rosing H, de Vries N, Meulendijks D, Cats A, Beijnen JH, Schellens JH, Huitema AD (2019) Pharmacokinetics of capecitabine and four metabolites in a heterogeneous population of cancer patients: a comprehensive analysis. CPT Pharmacometrics Syst Pharmacol 8(12):940\u2013950. https:\/\/doi.org\/10.1002\/psp4.12474","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"22","key":"4473_CR27","doi-asserted-by":"publisher","first-page":"6981","DOI":"10.3748\/wjg.v20.i22.6981","volume":"20","author":"L Huang","year":"2014","unstructured":"Huang L, Xu A-M, Li T-J, Han W-X, Xu J (2014) Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients? World J Gastroenterol 20(22):6981\u20136988. https:\/\/doi.org\/10.3748\/wjg.v20.i22.6981","journal-title":"World J Gastroenterol"},{"issue":"2","key":"4473_CR28","doi-asserted-by":"publisher","first-page":"G71","DOI":"10.1152\/ajpgi.1980.239.2.G71","volume":"239","author":"KA Kelly","year":"1980","unstructured":"Kelly KA (1980) Gastric emptying of liquids and solids: roles of proximal and distal stomach. Am J Physiol Gastrointest Liver Physiol 239(2):G71\u2013G76. https:\/\/doi.org\/10.1152\/ajpgi.1980.239.2.G71","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"issue":"4","key":"4473_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s002800050900","volume":"43","author":"B Reigner","year":"1999","unstructured":"Reigner B, Clive S, Cassidy J, Jodrell D, Schulz R, Goggin T, Banken L, Roos B, Utoh M, Mulligan T (1999) Influence of the antacid Maalox on the pharmacokinetics of capecitabine in cancer patients. Cancer Chemother Pharmacol 43(4):309\u2013315. https:\/\/doi.org\/10.1007\/s002800050900","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"4473_CR30","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1007\/s00280-019-03837-y","volume":"83","author":"M Sekido","year":"2019","unstructured":"Sekido M, Fujita K-I, Kubota Y, Ishida H, Takahashi T, Ohkuma R, Tsunoda T, Ishikawa F, Shibanuma M, Sasaki Y (2019) Rabeprazole intake does not affect systemic exposure to capecitabine and its metabolites, 5\u2032-deoxy-5-fluorocytidine, 5\u2032-deoxy-5-fluorouridine, and 5-fluorouracil. Cancer Chemother Pharmacol 83(6):1127\u20131135. https:\/\/doi.org\/10.1007\/s00280-019-03837-y","journal-title":"Cancer Chemother Pharmacol"},{"key":"4473_CR31","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/cpt.2444","volume":"111","author":"L van Doorn","year":"2021","unstructured":"van Doorn L, Heersche N, de Man FM, de Bruijn P, Bijl I, Oomen-de Hoop E, Eskens FA, van der Gaast A, Mathijssen RH, Bins S (2021) Effect of the Proton Pump Inhibitor Esomeprazole on the Systemic Exposure of Capecitabine: Results of A Randomized Crossover Trial. Clin Pharm Therap 111:455\u2013460. https:\/\/doi.org\/10.1002\/cpt.2444","journal-title":"Clin Pharm Therap"},{"issue":"5","key":"4473_CR32","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1007\/s40620-016-0309-2","volume":"29","author":"DG Moledina","year":"2016","unstructured":"Moledina DG, Perazella MA (2016) PPIs and kidney disease: from AIN to CKD. J Nephrol 29(5):611\u2013616. https:\/\/doi.org\/10.1007\/s40620-016-0309-2","journal-title":"J Nephrol"},{"issue":"5","key":"4473_CR33","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2125.2010.03623.x","volume":"69","author":"NA Helsby","year":"2010","unstructured":"Helsby NA, Lo WY, Simpson IJ, Voss DM, Logan KE, Searle M, Schollum JB, De Zoysa JR (2010) Omeprazole-induced acute interstitial nephritis is not related to CYP2C19 genotype or CYP2C19 phenotype. Br J Clin Pharmacol 69(5):516\u2013519. https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03623.x","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"4473_CR34","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jamainternmed.2015.7193","volume":"176","author":"B Lazarus","year":"2016","unstructured":"Lazarus B, Chen Y, Wilson FP, Sang Y, Chang AR, Coresh J, Grams ME (2016) Proton pump inhibitor use and the risk of chronic kidney disease. JAMA Intern Med 176(2):238\u2013246. https:\/\/doi.org\/10.1001\/jamainternmed.2015.7193","journal-title":"JAMA Intern Med"},{"issue":"1","key":"4473_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.clinthera.2005.01.005","volume":"27","author":"CM Walko","year":"2005","unstructured":"Walko CM, Lindley C (2005) Capecitabine: a review. Clin Ther 27(1):23\u201344. https:\/\/doi.org\/10.1016\/j.clinthera.2005.01.005","journal-title":"Clin Ther"},{"issue":"22","key":"4473_CR36","doi-asserted-by":"publisher","first-page":"2706","DOI":"10.3748\/wjg.v25.i22.2706","volume":"25","author":"G Bruno","year":"2019","unstructured":"Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C (2019) Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 25(22):2706\u20132719. https:\/\/doi.org\/10.3748\/wjg.v25.i22.2706","journal-title":"World J Gastroenterol"},{"issue":"5","key":"4473_CR37","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nrc.2017.13","volume":"17","author":"S Roy","year":"2017","unstructured":"Roy S, Trinchieri G (2017) Microbiota: a key orchestrator of cancer therapy. Nat Rev Cancer 17(5):271\u2013285. https:\/\/doi.org\/10.1038\/nrc.2017.13","journal-title":"Nat Rev Cancer"},{"key":"4473_CR38","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/bcp.14728","volume":"87","author":"JP Brown","year":"2021","unstructured":"Brown JP, Tazare JR, Williamson E, Mansfield KE, Evans SJ, Tomlinson LA, Bhaskaran K, Smeeth L, Wing K, Douglas IJ (2021) Proton pump inhibitors and risk of all-cause and cause-specific mortality: A cohort study. Br J Clin Pharmacol 87:3150\u20133161. https:\/\/doi.org\/10.1111\/bcp.14728","journal-title":"Br J Clin Pharmacol"},{"key":"4473_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01480-0","author":"X Wang","year":"2021","unstructured":"Wang X, Liu Q, Halfdanarson \u00d3\u00d6, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N (2021) Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer. https:\/\/doi.org\/10.1038\/s41416-021-01480-0","journal-title":"Br J Cancer"},{"key":"4473_CR40","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1002\/hep.31914","volume":"74","author":"H Kamal","year":"2021","unstructured":"Kamal H, Sadr-Azodi O, Engstrand L, Brusselaers N (2021) Association between proton pump inhibitor use and biliary tract cancer risk: a Swedish population-based cohort study. Hepatology 74:2021\u20132031. https:\/\/doi.org\/10.1002\/hep.31914","journal-title":"Hepatology"},{"issue":"12","key":"4473_CR41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0189114","volume":"12","author":"IC Hwang","year":"2017","unstructured":"Hwang IC, Chang J, Park SM (2017) Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: a Korean nationwide prospective cohort study. PLoS ONE 12(12):e0189114. https:\/\/doi.org\/10.1371\/journal.pone.0189114","journal-title":"PLoS ONE"},{"issue":"1","key":"4473_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinre.2020.02.017","volume":"45","author":"W-Y Lei","year":"2021","unstructured":"Lei W-Y, Wang J-H, Yi C-H, Liu T-T, Hung J-S, Wong M-W, Bair M-J, Vaezi MF, Orr WC, Chen C-L (2021) Association between use of proton pump inhibitors and colorectal cancer: a nationwide population-based study. Clin Res Hepatol Gastroenterol 45(1):101397. https:\/\/doi.org\/10.1016\/j.clinre.2020.02.017","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"44","key":"4473_CR43","doi-asserted-by":"publisher","first-page":"7716","DOI":"10.3748\/wjg.v27.i44.7716","volume":"27","author":"A Patel","year":"2021","unstructured":"Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J (2021) Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 27(44):7716. https:\/\/doi.org\/10.3748\/wjg.v27.i44.7716","journal-title":"World J Gastroenterol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00280-022-04473-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-022-04473-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,12]],"date-time":"2022-10-12T18:03:03Z","timestamp":1665597783000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00280-022-04473-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,13]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["4473"],"URL":"https:\/\/doi.org\/10.1007\/s00280-022-04473-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,13]]},"assertion":[{"value":"22 June 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}